ArticleFunctional & integrative genomics2025
mlstverse-web: advancing real-time identification of mycobacteria from sputum using targeted sequencing NALC-Seq.
Article in Functional & integrative genomics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Comparison of culture and culture-free methods for comprehensive identification of mycobacteria: a single-center prospective study.Journal of clinical microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
The identification of mycobacteria, including Mycobacterium tuberculosis (MTB) and non-tuberculous mycobacteria (NTM), remains a critical challenge in clinical and public health settings due to their pathogenicity and increasing drug resistance. Traditional diagnostic methods, such as PCR and mass spectrometry, are limited by species detectability and prolonged culture requirements. To address these limitations, this study introduces a novel approach, named NALC-Seq, which integrates next-generation sequencing (NGS) and target capture sequencing for the direct and comprehensive identification of mycobacteria from sputum samples. A total of 54 patients were prospectively or retrospectively enrolled between April 6, 2021, and November 8, 2022, and sputum samples were subjected to next generation sequencing. The NALC-Seq methodology utilizes custom-designed RNA probes for targeted enrichment of mycobacterial DNA, coupled with species identification via the mlstverse-web system. This system integrates web, upload, head, and cloud nodes to streamline data management and analysis. Our evaluation demonstrated that NALC-Seq achieved high sensitivity (98.1%) and accuracy (83.3%) in detecting diverse mycobacterial species, including rare and drug-resistant subspecies. There were discrepancies with MGIT-Seq in nine samples. These samples exhibited low smear positivity rates, and the detection of environmental mycobacteria suggested potential contamination. Furthermore, real-time identification using the MinION device significantly reduced the turnaround time from 686 to 19 h.These findings highlight the potential of NALC-Seq and mlstverse-web as an integrated diagnostic solution for overcoming the limitations of current methods. The proposed approach offers a rapid, accurate, and comprehensive strategy for mycobacterial identification, with significant implications for clinical diagnostics and public health surveillance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.